Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target at $185.20

Shares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirteen research firms that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $185.20.

Several equities analysts have recently commented on RGEN shares. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating for the company. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, January 3rd. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. UMB Bank n.a. lifted its position in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 130 shares during the last quarter. Blue Trust Inc. raised its holdings in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after buying an additional 127 shares during the last quarter. Resources Management Corp CT ADV purchased a new stake in Repligen during the 3rd quarter valued at $37,000. Quarry LP grew its holdings in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 239 shares during the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Repligen in the third quarter valued at about $45,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

Shares of Repligen stock traded up $0.16 during trading on Friday, hitting $154.86. 552,691 shares of the stock were exchanged, compared to its average volume of 459,931. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The stock has a market capitalization of $8.68 billion, a price-to-earnings ratio of -418.53, a price-to-earnings-growth ratio of 4.64 and a beta of 0.97. The company has a fifty day moving average price of $146.77 and a 200-day moving average price of $143.55. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. During the same quarter last year, the company posted $0.23 EPS. Repligen's quarterly revenue was up 9.7% compared to the same quarter last year. As a group, equities analysts predict that Repligen will post 1.54 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.